J&J succeeds in trial for drug delivery system (JNJ:NYSE)

robot
Abstract generation in progress

Johnson & Johnson (JNJ) announced positive results from a Phase 1 trial for a novel drug delivery system. This system is designed to administer its bladder cancer therapy, erdafitinib, which was developed in collaboration with Otsuka (OTSKY) (OTSKF). The trial successfully met its primary safety endpoint.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin